The Montelukast Therapy in Asthmatic Children with and without Food Allergy: Does It Make Any Difference?


ŞAHİNER Ü. M. , Yilmaz E. A. , Fontanella S., Haider S., UYSAL SOYER Ö., Custovic A., ...More

INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2021 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Publication Date: 2021
  • Doi Number: 10.1159/000517865
  • Journal Name: INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
  • Journal Indexes: Science Citation Index Expanded, Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database
  • Keywords: Asthma, Asthma control test, Children, Cysteinyl leukotrienes, Exhaled breath condensate, Fractional exhaled nitric oxide, FEV1, Food allergy, Methacholine, Montelukast, Prostaglandin D2, EXHALED BREATH CONDENSATE, RECEPTOR ANTAGONIST, PROSTAGLANDIN D-2, LUNG-FUNCTION, LEUKOTRIENE, FLUTICASONE, PREDICTORS, INHALATION, PHENOTYPES, ENDOTYPES

Abstract

Introduction: Children with food allergy are at increased risk for asthma and asthma morbidity. Since leukotrienes are implicated in the pathogenesis of both asthma and probably in food allergies, we hypothesized that asthmatic children with concomitant food allergy may have a favorable response to antileukotriene treatment. Methods: Asthmatic children aged 6-18 years with and without food allergy were treated with montelukast and placebo in a double-blind, placebo-controlled cross-over parallel-group study. The primary outcome of the study was improvement in FEV1%. Asthma control tests, spirometry and methacholine challenges were performed as well as Fractional Exhaled Nitric Oxide (FeNO) levels. PGD2, CystLT, and lipoxin levels were measured in exhaled breath condensate (EBC). Results: A total of 113 children were enrolled and 87 completed the study in accordance with the protocol. At baseline, children with food allergy and asthma (FAA) had higher levels of PGD2 and CysLT levels in the EBC than children with asthma alone (AA) (p < 0.001 for each). In the montelukast arm, although FEV1% was significantly higher in the FAA group compared to AA (p = 0.005), this effect was linked to the baseline difference of FEV1% between both arms. Montelukast treatment failed to improve FEV1% in both groups compared to the placebo. No effect of montelukast was observed in the remaining study parameters. Conclusion: Although children with FAA do not show a more favorable response to montelukast treatment compared to AA, a significant difference between baseline PGD2 and CystLT levels between FAA and AA groups may point to a different endotype of childhood asthma.